查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1536222

創傷性腦損傷治療的全球市場

Traumatic Brain Injury Therapeutics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 149 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球創傷性腦損傷治療市場預計將達到 137 億美元

Masu 表示，2023 年全球創傷性腦損傷治療市場規模預計為 59 億美元，預計到 2030 年將達到 137 億美元，2023-2030 年分析期間複合年成長率為 12.7%。乙醯膽鹼酯酶抑制劑是本報告分析的細分市場之一，複合年成長率為12.5%，預計到分析期末將達到38億美元。分析期間，促紅血球生成素製藥業務的複合年成長率預計為 11.5%。

美國市場預計將成長16億美元，中國複合年成長率為11.8%

預計 2023 年美國創傷性腦損傷治療市場規模將達 16 億美元。中國作為世界第二大經濟體，預計2030年市場規模將達21億美元，2023-2030年分析期間複合年成長率為11.8%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 11.6% 和 10.8%。在歐洲，德國的複合年成長率預計約為 9.3%。

全球創傷性腦損傷治療市場 - 主要趨勢和促進因素總結

創傷性腦損傷（TBI）是一個重大的公共衛生問題，每年影響全球數百萬人。當大腦受到外力損傷時，例如跌倒、車禍、運動傷害或攻擊，就會發生 TBI。 TBI 的嚴重程度從輕度腦震盪到嚴重腦損傷，可能導致長期殘疾甚至死亡。目前 TBI 的治療策略包括急性介入（例如手術）以降低顱內壓並防止進一步損傷，以及長期復健以解決認知、身體和情緒缺陷。藥物治療的目的是控制症狀並預防發炎、氧化壓力和興奮性毒性引起的繼發性腦損傷。儘管可用的治療方法多種多樣，但能夠顯著改變 TBI 病程的有效治療方法有限，這凸顯了對創新治療方法的需求。

對 TBI病理學的了解的最新進展為新的治療策略開闢了道路。對神經保護劑（例如抗氧化劑、發炎劑和鈣通道阻斷劑）的研究表明，它們具有減少初次損傷後繼發性損傷的潛力。幹細胞療法也是一個新興領域，為組織再生和功能恢復提供了潛力。此外，生物標記發現的進步正在增強我們準確診斷 TBI 和監測治療效果的能力，為更個人化的治療計劃鋪平道路。高壓氧氣療法和經顱磁刺激等非藥物干預措施也正在研究其促進神經可塑性和恢復的潛力。這些創新方法源自於對 TBI 複雜機制的更深入了解，旨在為患者提供更有效、更全面的治療。

TBI 治療市場的成長受到多種因素的推動。由於體育活動、軍事衝突、交通事故等導致的TBI發病率不斷增加，增加了對有效治療的需求。診斷工具的技術進步，例如先進的影像技術和生物標記檢測，提高了 TBI 的診斷準確性和治療進展的監測。再生醫學領域的不斷擴大，特別是幹細胞研究，正在為以前不可能的治療性介入提供新的途徑。此外，人們越來越認知到 TBI 對生活品質具有長期影響，從而推動了對新治療方法研發的投資。旨在改善 TBI 患者治療效果的政府措施和資金，以及學術機構和製藥公司之間的合作，也正在推動這一領域的創新。此外，個人化醫療的興起正在促進客製化治療方法的開發，以滿足每位患者的獨特需求，從而提高 TBI 治療的整體有效性。這些因素結合在一起，使創傷性腦損傷治療市場充滿活力並迅速發展。

受訪企業範例（共86家）

  • Abliva
  • Algernon Pharmaceuticals Inc.
  • Altasciences
  • Astrocyte Pharmaceuticals Inc.
  • Beyond Barriers Therapeutics, Inc.
  • Cellvation, Inc.
  • Ischemix
  • Mitochon Pharmaceuticals
  • NervGen Pharma Corp.
  • Neuren Pharmaceuticals Ltd.
  • SanBio Company Limited
  • Symbinas Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • ZyVersa Therapeutics, Inc.

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他領域

第4章 比賽

簡介目錄
Product Code: MCP26850

Global Traumatic Brain Injury Therapeutics Market to Reach US$13.7 Billion by 2030

The global market for Traumatic Brain Injury Therapeutics estimated at US$5.9 Billion in the year 2023, is expected to reach US$13.7 Billion by 2030, growing at a CAGR of 12.7% over the analysis period 2023-2030. Acetylcholinesterase Inhibitors, one of the segments analyzed in the report, is expected to record a 12.5% CAGR and reach US$3.8 Billion by the end of the analysis period. Growth in the Erythropoietin Drugs segment is estimated at 11.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 11.8% CAGR

The Traumatic Brain Injury Therapeutics market in the U.S. is estimated at US$1.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 11.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.6% and 10.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.3% CAGR.

Global Traumatic Brain Injury Therapeutics Market - Key Trends and Drivers Summarized

Traumatic brain injury (TBI) is a significant public health concern, affecting millions of people worldwide each year. TBI occurs when an external force injures the brain, which can result from falls, motor vehicle accidents, sports injuries, or assaults. The severity of TBI ranges from mild concussions to severe brain damage, leading to long-term disabilities or even death. Current therapeutic strategies for TBI include acute interventions, such as surgery to reduce intracranial pressure and prevent further injury, as well as long-term rehabilitation efforts to address cognitive, physical, and emotional impairments. Pharmacological treatments are aimed at managing symptoms and preventing secondary brain damage caused by inflammation, oxidative stress, and excitotoxicity. Despite the array of interventions, effective treatments that can significantly alter the course of TBI remain limited, highlighting a critical need for innovative therapeutic approaches.

Recent advancements in the understanding of TBI pathophysiology have paved the way for novel therapeutic strategies. Research into neuroprotective agents, such as antioxidants, anti-inflammatory drugs, and calcium channel blockers, shows promise in mitigating the secondary damage following the initial injury. Stem cell therapy is another emerging field, offering potential for tissue regeneration and functional recovery. Additionally, advancements in biomarker discovery are enhancing the ability to diagnose TBI accurately and monitor treatment efficacy, paving the way for more personalized treatment plans. Non-pharmacological interventions, including hyperbaric oxygen therapy and transcranial magnetic stimulation, are also being explored for their potential to enhance neuroplasticity and recovery. These innovative approaches are driven by a deeper understanding of the complex mechanisms underlying TBI, aiming to provide more effective and comprehensive care for patients.

The growth in the TBI therapeutics market is driven by several factors. The increasing incidence of TBI due to sports activities, military conflicts, and road accidents has heightened the demand for effective treatments. Technological advancements in diagnostic tools, such as advanced imaging techniques and biomarker assays, have improved the accuracy of TBI diagnosis and the monitoring of treatment progress. The expanding field of regenerative medicine, particularly stem cell research, offers new avenues for therapeutic interventions that were previously unattainable. Moreover, the growing awareness of the long-term impact of TBI on quality of life is propelling investment in research and development of new treatments. Government initiatives and funding aimed at improving outcomes for TBI patients, along with collaborations between academic institutions and pharmaceutical companies, are also fostering innovation in this field. Additionally, the rise of personalized medicine is driving the development of tailored therapeutic approaches that address the unique needs of each patient, enhancing the overall efficacy of TBI treatments. Collectively, these factors are contributing to a dynamic and rapidly evolving market for traumatic brain injury therapeutics.

Select Competitors (Total 86 Featured) -

  • Abliva
  • Algernon Pharmaceuticals Inc.
  • Altasciences
  • Astrocyte Pharmaceuticals Inc.
  • Beyond Barriers Therapeutics, Inc.
  • Cellvation, Inc.
  • Ischemix
  • Mitochon Pharmaceuticals
  • NervGen Pharma Corp.
  • Neuren Pharmaceuticals Ltd.
  • SanBio Company Limited
  • Symbinas Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • ZyVersa Therapeutics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Traumatic Brain Injury Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of TBI Spurs Demand for Effective Therapies
    • Advances in Diagnostic Tools Propel Growth in Market Adoption
    • Technological Innovations in Imaging Techniques Expand Addressable Market Opportunity
    • Emergence of Neuroprotective Agents Strengthens Business Case for Novel Treatments
    • Development of Stem Cell Therapies Generates New Market Opportunities
    • Growing Focus on Personalized Medicine Drives Adoption of Tailored Therapeutic Approaches
    • Enhanced Understanding of TBI Pathophysiology Drives Market Dynamics
    • Growing Awareness of Long-Term Impact of TBI Throws the Spotlight On Need for Comprehensive Care
    • Expanding Field of Regenerative Medicine Sustains Growth in Therapeutic Interventions
    • Integration of Biomarker Discovery and Use in Diagnostics and Treatment Monitoring Generates Demand
    • Non-Pharmacological Interventions, Such as Hyperbaric Oxygen Therapy, Propel Market Growth
    • Increasing Number of Sports-Related TBIs Drives Market Demand
    • Advancements in Transcranial Magnetic Stimulation Generate New Treatment Opportunities
    • Here's the Story: Impact of Military Conflicts on TBI Incidence and Therapeutic Needs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Traumatic Brain Injury Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Traumatic Brain Injury Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Traumatic Brain Injury Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Acetylcholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Acetylcholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Acetylcholinesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Erythropoietin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Erythropoietin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Erythropoietin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Growth Hormone Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Growth Hormone Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Growth Hormone Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Stem Cells Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Stem Cells Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Stem Cells Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Japan 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • CHINA
    • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: China 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Traumatic Brain Injury Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Traumatic Brain Injury Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: France 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Germany 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Italy 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: UK 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 56: Rest of World Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of World Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Rest of World 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030

IV. COMPETITION